Cns Pharmaceuticals Stock News

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Cns Pharmaceuticals Inc (CNSP) shares closed 4.7% lower than its previous 52 week low, giving the company a market cap of $21M. The stock is currently down 57.4% year-to-date, down 59.0% over the past 12 months, and down 83.4% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 18.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 90.2% The company's stock price performance over the past 12 months lags the peer average by 89.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cns Pharmaceuticals Inc (CNSP) shares closed today at 1.5% above its 52 week low of $0.79, giving the company a market cap of $22M. The stock is currently down 54.8% year-to-date, down 54.8% over the past 12 months, and down 82.4% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 5.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 91.2% The company's stock price performance over the past 12 months lags the peer average by 80.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Equities analysts expect CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) to announce ($0.31) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for CNS Pharmaceuticals earnings. CNS Pharmaceuticals reported earnings per share of ($0.18) in the same quarter last year, which suggests a negative year-over-year growth rate of 72.2%. []

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 260,000 shares, a decline of 19.7% from the October 31st total of 323,900 shares. Approximately 1.5% of the shares of the company are short sold. Based on an average daily []

HOUSTON, Dec. 2, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has

Glioblastoma multiforme (GBM) is an aggressive and deadly form of brain cancer. For those afflicted, the prognosis is bleak but biopharmaceutical company CNS Pharmaceuticals (NASDAQ:CNSP) Inc is pro

Renaissance Technologies LLC decreased its holdings in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 40.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 432,109 shares of the companys stock after selling 290,651 shares during the quarter. Renaissance Technologies LLC owned approximately 1.70% of CNS []

LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary

HOUSTON, Sept. 30, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a

HOUSTON, Aug. 13, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary

These penny stocks pushed up in recent trading; are they worth watching? The post Best Penny Stocks to Buy Right Now?

The stock price of CNS Pharmaceuticals Inc (NASDAQ: CNSP) increased by over 10% pre-market. This is why it happened.

Glioblastoma multiforme, or GBM, may not sound familiar but if you suffer from this aggressive form of brain cancer the prognosis isn't good. Biopharmaceutical company CNS Pharmaceuticals Inc (NASDAQ

HOUSTON, July 1, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary a